The US Biotechnology Market Outlook to 2016 - Future Growth Led by Surging Biotech Application in Agriculture, Health and Industrial Sector
The report titled ‘The US Biotechnology Market Outlook to 2016 – Future Growth Led by Surging Biotech Application in Agriculture, Health and Industrial Sector’ provides a detailed description of the biotechnology market scenario in the US and a comprehensive analysis of the various qualitative and quantitative factors that are influencing the market. The report depicts the size of the biotech industry, biopharmaceuticals, biopesticides and bioseeds, biofuel and bioenzymes segments in the US, a competitive landscape and profiles of key players in these segments and the recent trends and developments in the biotechnology market in the US. The report also covers future outlook and projections for the different segments as well as the overall US biotechnology market on the basis of several industry factors that will shape the growth of this market in next five years.
The biotechnology market in the US has witnessed a rapid expansion in recent years driven by increased biotechnology applications in various sectors such as agriculture, food, health, medical and environmental sciences. The application in the human health dominates the US biotechnology market followed by agricultural and industrial applications. The biotechnology industry in the US is comprised of large multinational corporations, small entrepreneurial firms, various public and private research entities, dedicated biotechnology investment companies, bioinformatics companies and academia. The US biotechnology industry revenues have increased from USD 73 billion in 2006 to USD ~ billion in 2011 by growing at a CAGR of ~% during 2006-2011. The falling supply and production of oil, gas and coal and wide attention to the environmental impacts has also increased the demand for biotechnology engineered energy sources such as biofuels.
The US biotechnology market can be classified into three segments- Bio-Pharma, Industrial biotechnology and Agricultural biotechnology. The bio-pharma represents the largest segment in the US biotechnology market. This is followed by industrial biotechnology which is the second largest contributor in the US biotechnology market. Biologic drugs are gradually increasing their share over the period. Biological drugs are generally more expensive than the conventional drugs thus acting as a key revenue earners for producers. The total US biologic drugs market grew from USD ~ billion in 2006 to USD ~ billion in 2011 at a 5 year CAGR of 7.7%. Biologic drugs has high potential for future growth because of better long term outcomes with fewer costly side effects. Bristol-Myers Squibb is the largest company in the US in terms of biopharmaceutical drugs sales. The company held a market share of ~% and recorded sales of USD ~ billion. The company focuses on developing drugs in the oncology therapeutic class.
The agricultural biotechnology in the US is widely popular among farmers owing to the benefits of tools like genetic engineering that has made crop production cheaper and more manageable. The use of biotech crops that are unaffected by plant diseases and insect pests also have reduced the use of synthetic pesticides. The US agricultural biotechnology market has grown at a CAGR of ~% during 2006-2011 to USD ~ million in 2011.
The biotech crops accounts for majority of the US agricultural biotechnology market while the bio-pesticides contribute very less as compared to biotech crops. The contribution of biotech crops in the US agricultural biotechnology market have increased from ~% to ~% over the five year duration of 2006-2011 while on the other hand the contribution of bio-pesticides have declined from ~% to ~% during the same period.
In 2011, the US accounted for almost 3/4th of the total biotech crop production across the world with total hectarage of ~ million hectares dedicated to the production of biotech crops. The bio-pesticides market in the US has recorded a CAGR of ~% during 2006-2011. After 2009, the market gained momentum again and was recorded at USD ~ million in 2011. This reflects an increase in the adoption of bio-pesticides by the US farmers as a replacement to the toxic chemical pesticides. The various segments for the consumption of bio-pesticides in the US market are organic agricultural industry, vegetable farming, orchard crops and berries, federal and municipal programs for the management and treatment of forests, water resources and green belts in urban areas.
The development and adoption of industrial biotechnology has witnessed an unprecedented growth in the US in last five years. The substitution of conventional liquid fuels with liquid biofuels is widely considered as an important step towards energy security by reducing crude petroleum imports. The biofuel industry in the US grew at a CAGR of ~% from the period 2006-2011. The market in the US has increased by ~% in 2011 to USD ~ million due to rise in the government mandate blending rate targets. In the US the Environmental Protection Agency (EPA) has mandated a minimum level of biofuel consumption between 2006 and 2022. The market is expected to experience a CAGR of 12.1% from 2012-2016 following which the industry is expected to record revenue of USD ~ million in 2016. The US market for industrial enzymes can be categorized into – Detergent Enzymes, Technical Enzymes, Food & beverage enzymes and Animal Feed enzymes. The US market for bio-enzymes was registered revenues of USD ~ million in 2011 while in 2006 the size of the market was USD ~ million. This accounts for a CAGR of ~% during 2006-2011.
The various trends such as growing old population, increasing emphasis on the sustainable renewable energy alternatives to reduce the dependency on the import of the oil, decreasing arable land and the increasing demand for food and the ability of biotech products and services to meet all these demands are expected to drive the US biotechnology market positively in next five years. Due to these factors the US biotechnology market is expected to grow at a CAGR of 10.2% during 2012-2016 to reach USD ~ million in 2016 from USD ~ million in 2012.
Key Topics Covered in the Report:
The biotechnology market in the US has witnessed a rapid expansion in recent years driven by increased biotechnology applications in various sectors such as agriculture, food, health, medical and environmental sciences. The application in the human health dominates the US biotechnology market followed by agricultural and industrial applications. The biotechnology industry in the US is comprised of large multinational corporations, small entrepreneurial firms, various public and private research entities, dedicated biotechnology investment companies, bioinformatics companies and academia. The US biotechnology industry revenues have increased from USD 73 billion in 2006 to USD ~ billion in 2011 by growing at a CAGR of ~% during 2006-2011. The falling supply and production of oil, gas and coal and wide attention to the environmental impacts has also increased the demand for biotechnology engineered energy sources such as biofuels.
The US biotechnology market can be classified into three segments- Bio-Pharma, Industrial biotechnology and Agricultural biotechnology. The bio-pharma represents the largest segment in the US biotechnology market. This is followed by industrial biotechnology which is the second largest contributor in the US biotechnology market. Biologic drugs are gradually increasing their share over the period. Biological drugs are generally more expensive than the conventional drugs thus acting as a key revenue earners for producers. The total US biologic drugs market grew from USD ~ billion in 2006 to USD ~ billion in 2011 at a 5 year CAGR of 7.7%. Biologic drugs has high potential for future growth because of better long term outcomes with fewer costly side effects. Bristol-Myers Squibb is the largest company in the US in terms of biopharmaceutical drugs sales. The company held a market share of ~% and recorded sales of USD ~ billion. The company focuses on developing drugs in the oncology therapeutic class.
The agricultural biotechnology in the US is widely popular among farmers owing to the benefits of tools like genetic engineering that has made crop production cheaper and more manageable. The use of biotech crops that are unaffected by plant diseases and insect pests also have reduced the use of synthetic pesticides. The US agricultural biotechnology market has grown at a CAGR of ~% during 2006-2011 to USD ~ million in 2011.
The biotech crops accounts for majority of the US agricultural biotechnology market while the bio-pesticides contribute very less as compared to biotech crops. The contribution of biotech crops in the US agricultural biotechnology market have increased from ~% to ~% over the five year duration of 2006-2011 while on the other hand the contribution of bio-pesticides have declined from ~% to ~% during the same period.
In 2011, the US accounted for almost 3/4th of the total biotech crop production across the world with total hectarage of ~ million hectares dedicated to the production of biotech crops. The bio-pesticides market in the US has recorded a CAGR of ~% during 2006-2011. After 2009, the market gained momentum again and was recorded at USD ~ million in 2011. This reflects an increase in the adoption of bio-pesticides by the US farmers as a replacement to the toxic chemical pesticides. The various segments for the consumption of bio-pesticides in the US market are organic agricultural industry, vegetable farming, orchard crops and berries, federal and municipal programs for the management and treatment of forests, water resources and green belts in urban areas.
The development and adoption of industrial biotechnology has witnessed an unprecedented growth in the US in last five years. The substitution of conventional liquid fuels with liquid biofuels is widely considered as an important step towards energy security by reducing crude petroleum imports. The biofuel industry in the US grew at a CAGR of ~% from the period 2006-2011. The market in the US has increased by ~% in 2011 to USD ~ million due to rise in the government mandate blending rate targets. In the US the Environmental Protection Agency (EPA) has mandated a minimum level of biofuel consumption between 2006 and 2022. The market is expected to experience a CAGR of 12.1% from 2012-2016 following which the industry is expected to record revenue of USD ~ million in 2016. The US market for industrial enzymes can be categorized into – Detergent Enzymes, Technical Enzymes, Food & beverage enzymes and Animal Feed enzymes. The US market for bio-enzymes was registered revenues of USD ~ million in 2011 while in 2006 the size of the market was USD ~ million. This accounts for a CAGR of ~% during 2006-2011.
The various trends such as growing old population, increasing emphasis on the sustainable renewable energy alternatives to reduce the dependency on the import of the oil, decreasing arable land and the increasing demand for food and the ability of biotech products and services to meet all these demands are expected to drive the US biotechnology market positively in next five years. Due to these factors the US biotechnology market is expected to grow at a CAGR of 10.2% during 2012-2016 to reach USD ~ million in 2016 from USD ~ million in 2012.
Key Topics Covered in the Report:
- The market size of the US Biotechnology Market by revenue for the period 2006-2011.
- Market segmentation of the US biotechnology market on the basis of bio-pharmaceuticals, agricultural biotechnology and industrial, 2006-2011.
- Market size, introduction and future outlook/projections of the US bio-pharmaceutical market.
- Company Profiles of major companies in the US bio-phrmaceuticals market.
- Market size, introduction and future outlook/projections of the US agriculture biotechnology market.
- Market segmentation of the US agricultural biotechnology market on the basis of biotech crops and bio-pesticides.
- Market size, introduction and future outlook/projections of the biotech crops and bio-pesticides market of the US.
- Trends and Development of the US agricultural biotechnology market.
- Company Profiles of major companies in the US agricultural biotechnology market.
- Market segmentation of the US industrial biotechnology market on the basis of biofuels and bio-enzymes.
- Market size, introduction and future outlook/projections of the biofuels and bio-enzymes market of the US.
- Trends and Development of the US industrial biotechnology market.
- Company Profiles of major companies in the US bio-enzymes market.
- Future outlook and projections of the US biotechnology market, 2012-2016.
1. THE US BIOTECHNOLOGY MARKET INTRODUCTION
2. THE US BIOTECHNOLOGY MARKET SIZE BY REVENUE, 2006-2011
3. THE US BIOTECHNOLOGY MARKET SEGMENTATION BY APPLICATION, 2006-2011
3.1. The US Bio-Pharmaceutical/Biologics Market Size and Introduction, 2006-2011
3.1.1. Top Selling Biologic Drugs, 2010
3.1.2. The US Bio-Pharmaceuticals Market Trends And Developments
Bio-Pharmaceutical Companies Focus on Outsourcing as Short Term Strategy
High Approvals Increasing the Number of Bio-Pharmaceutical Products
3.1.3. Top US Biopharmaceutical Companies Market Share, 2011
3.1.4. Biologic Drugs Future Projections, 2012-2016
3.1.5. Major Bio-Pharmaceutical Company Profiles
3.1.5.1. Pfizer Inc
Company Overview
Business Strategies
Financial Performance
3.1.5.2. Merck & Co
Company Overview
Business Strategies
Financial Performance
3.1.5.3. Novartis
Company Overview
Business Strategies
Financial Performance
3.1.5.4. AstraZeneca
Company Overview
Business Strategies
Financial Performance
3.1.5.5. GlaxoSmithKline
Company Overvie
Business Strategies
Financial Performance
3.1.6. Macro Economic and Industry Indicators: Current and Projections
3.1.6.1. Population, 2005-2015
3.1.6.2. Inpatient Admissions & Outpatients Visits, 2005-2010
3.1.6.3. Number of People with Health Insurance, 2005-2010
3.1.6.4. Prescription Drug Price index, 2005-2015
3.1.6.5. Personal Disposable Income, 2005-2015
3.2. The US Agricultural Biotechnology Market Size and Introduction 2006-2011
3.2.1. The US Agricultural Biotechnology Market Segmentation, 2006-2011
3.2.2. The US Biotechnology Crop Market Size, 2006-2011
3.2.2.1. By Crop Area, 2006-2011
3.2.2.2. By Revenue, 2006-2011
3.2.3. The US Biotechnology Crop Market Future Outlook/Projections, 2012-2016
3.2.3.1. By Crop Area and Revenue, 2012-2016
3.2.4. The US Bio-Pesticides Market Size and Introduction, 2006-2011
3.2.5. The US Bio-Pesticides Market Future Outlook and Projections, 2012-2016
3.2.6. The US Agriculture Biotechnology Market Trends and Developments
Labeling of GM Food in The US Market
The US Supermarkets Selling Privately Labeled Organic Products
3.2.7. The US Agricultural Biotechnology Future Outlook and Projections 2012-2016
3.2.8. Company Profiles of Major Companies in the US Agricultural Biotechnology Market
3.3. The US Industrial Biotechnology Market Size and Introduction 2006-2011
3.3.1. The US Industrial Biotechnology Market Segmentation, 2006-2011
3.3.2. The US Biofuel Market Size by Revenue, 2006-2011
3.3.2.1. The US Biofuel Market Size by Production and Consumption, 2005-2011
3.3.2.2. The US Fuel Ethanol Import, 2005-2011
3.3.2.3. The US Bio Diesel Import and Export, 2005-2011
3.3.3. The US Biofuel Market Segmentation, 2006-2011
3.3.3.1. By Fuel Ethanol and Bio Diesel, 2006-2011
3.3.4. The US Biofuel Industry Future Projections, 2012-2016
3.3.4.1. By Value, 2012-2016
3.3.4.2. By Fuel Ethanol and Bio Diesel, 2012-2016
3.3.5. The US Bio-Enzymes Market Size by Revenue, 2006-2011
3.3.6. Company Profiles of Major Companies in US Bio-Enzymes Market, 2011
3.3.6.1. Novozymes
Company Overview
Business Strategies
Financial Performance
3.3.6.2. Genencor
Company Overview
Business Strategies
Financial Performance
3.3.7. The US Bio-Enzymes Market Future Outlook and Projections, 2012-2016
3.3.8. The US Industrial Biotechnology Market Trends And Developments
Increasing Government Blending Rate Targets
Shifting Focus Towards Advanced Biofuels
Growing Application of Industrial Enzymes For Biofuels
3.3.9. The US Industrial Biotechnology Future Outlook and Projections, 2012-2016
4. The US Biotechnology Market Future Outlook and Projections
4.1. Cause and Effect Relationship Between Industry Factors and The US Biotechnology Industry
5. Appendix
5.1. Market Definitions
5.2. Abbreviations
5.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Scenario Analysis
Final Conclusion
5.4. Disclaimer
LIST OF FIGURES
Figure 1: US Biotechnology Market Size in USD Million, 2006-2011
Figure 2: The US Biotechnology Market Segmentation by Bio-Pharmaceuticals,Agriculture Biotech and Industrial Biotechnology in Percentage, 2006-2011
Figure 3: The US Biopharmaceuticals Market Size by Revenue in USD Billion, 2006-2011
Figure 4: Market Share of the Major Biopharmaceutical Companies in the US on the Basis of Revenue, Percentage, 2011
Figure 5: Future Projections of the US Biologic Drug Sales in USD Billion, 2012-2016
Figure 6: Pfizer Biopharmaceutical Sales in the US in USD Billion, 2005-2011
Figure 7: Merck Pharmaceutical Drugs Sales in the US in USD Billion, 2009-2011
Figure 8: Novartis Drug Revenue in the US in USD Billion, 2005-2011
Figure 9: AstraZeneca Pharmaceutical Drug Sales in USD Billion, 2005-2011
Figure 10: GlaxoSmithKline Pharmaceutical Drug Sales in the US in USD Billion, 2007-2011
Figure 11: The US Population in Million, 2005-2015
Figure 12: Inpatient Admissions in Community Hospitals in the US in Million, 2005-2010
Figure 13: Outpatient Visits in Community Hospitals in the US in Million, 2005-2010
Figure 14: Total Number of People in the US with Health Insurance in Million, 2005-2010
Figure 15: The US Prescription Drug Price Index, 2005-2015
Figure 16: Personal Disposable Income in the US in USD Billion, 2005-2015
Figure 17: The US Agriculture Biotechnology Market Size in USD Million, 2006-2011
Figure 18: The US Agriculture Biotechnology Market Segmentation by Biotech Crops and Bio-Pesticides, 2006-2011
Figure 19: The US Biotechnology Crop Market Size in Million Hectares, 2006-2011
Figure 20: The US Biotechnology Crop Market Size in USD Million, 2006-2011
Figure 21: The US Biotechnology Crop Market Size in Million Hectares and USD Million, 2012-2016
Figure 22: The US Bio-Pesticides Market Size in USD Million, 2006-2011
Figure 23: The US Bio-Pesticides Market Size in USD Million, 2012-2016
Figure 24: The US Agricultural Biotechnology Market Size in USD Million, 2012-2016
Figure 25: The US Industrial Biotechnology Market Size in USD Million, 2006-2011
Figure 26: The US Industrial Biotechnology Market Segmentation in Percentage, 2006-2011
Figure 27: The US Biofuel Market Size on the Basis of Revenue in USD Million, 2006-2011
Figure 28: The US Biofuel Market Size on the Basis of Production, in Thousands Barrel per Day, 2005-2011
Figure 29: The US Biofuel Market Size on the Basis of Consumption, in Thousands Barrel Per Day, 2005-2011
Figure 30: The US Fuel Ethanol Import in Thousand Barrels from 2005-2011 and Export in Thousands Barrels per Year, 2010 and 2011
Figure 31: The US Bio Diesel Import and Export, in Thousands Barrels per Year, 2006-2011
Figure 32: The US Bio Diesel Lifecycle
Figure 33: The US Biofuel Market Segmentation by Fuel Ethanol and Bio Diesel on the Basis of Production in Thousands Barrels per Day, 2006-2011
Figure 34: The US Biofuel Market Segmentation by Fuel Ethanol and Bio Diesel on the Basis of Consumption in Thousands Barrels per Day, 2006-2011
Figure 35: The US Biofuel Market Projections by Revenue in USD Million, 2012-2016
Figure 36: The US Bio Enzymes Market Size in USD Million, 2006-2011
Figure 37: Market share of Major Companies in the US Enzymes Market, 2011
Figure 38: Novozymes Total Sales in USD Million, 2007-2011
Figure 39: Novozymes R&D Costs in USD Million, 2007-2011
Figure 40: The US Bio-Enzymes Market Size in USD Million, 2012-2016
Figure 41: The US Industrial Biotechnology Market Size in USD Million, 2012-2016
Figure 42: The US Biotechnology Market Size in USD Million, 2012-2016
Figure 1: US Biotechnology Market Size in USD Million, 2006-2011
Figure 2: The US Biotechnology Market Segmentation by Bio-Pharmaceuticals,Agriculture Biotech and Industrial Biotechnology in Percentage, 2006-2011
Figure 3: The US Biopharmaceuticals Market Size by Revenue in USD Billion, 2006-2011
Figure 4: Market Share of the Major Biopharmaceutical Companies in the US on the Basis of Revenue, Percentage, 2011
Figure 5: Future Projections of the US Biologic Drug Sales in USD Billion, 2012-2016
Figure 6: Pfizer Biopharmaceutical Sales in the US in USD Billion, 2005-2011
Figure 7: Merck Pharmaceutical Drugs Sales in the US in USD Billion, 2009-2011
Figure 8: Novartis Drug Revenue in the US in USD Billion, 2005-2011
Figure 9: AstraZeneca Pharmaceutical Drug Sales in USD Billion, 2005-2011
Figure 10: GlaxoSmithKline Pharmaceutical Drug Sales in the US in USD Billion, 2007-2011
Figure 11: The US Population in Million, 2005-2015
Figure 12: Inpatient Admissions in Community Hospitals in the US in Million, 2005-2010
Figure 13: Outpatient Visits in Community Hospitals in the US in Million, 2005-2010
Figure 14: Total Number of People in the US with Health Insurance in Million, 2005-2010
Figure 15: The US Prescription Drug Price Index, 2005-2015
Figure 16: Personal Disposable Income in the US in USD Billion, 2005-2015
Figure 17: The US Agriculture Biotechnology Market Size in USD Million, 2006-2011
Figure 18: The US Agriculture Biotechnology Market Segmentation by Biotech Crops and Bio-Pesticides, 2006-2011
Figure 19: The US Biotechnology Crop Market Size in Million Hectares, 2006-2011
Figure 20: The US Biotechnology Crop Market Size in USD Million, 2006-2011
Figure 21: The US Biotechnology Crop Market Size in Million Hectares and USD Million, 2012-2016
Figure 22: The US Bio-Pesticides Market Size in USD Million, 2006-2011
Figure 23: The US Bio-Pesticides Market Size in USD Million, 2012-2016
Figure 24: The US Agricultural Biotechnology Market Size in USD Million, 2012-2016
Figure 25: The US Industrial Biotechnology Market Size in USD Million, 2006-2011
Figure 26: The US Industrial Biotechnology Market Segmentation in Percentage, 2006-2011
Figure 27: The US Biofuel Market Size on the Basis of Revenue in USD Million, 2006-2011
Figure 28: The US Biofuel Market Size on the Basis of Production, in Thousands Barrel per Day, 2005-2011
Figure 29: The US Biofuel Market Size on the Basis of Consumption, in Thousands Barrel Per Day, 2005-2011
Figure 30: The US Fuel Ethanol Import in Thousand Barrels from 2005-2011 and Export in Thousands Barrels per Year, 2010 and 2011
Figure 31: The US Bio Diesel Import and Export, in Thousands Barrels per Year, 2006-2011
Figure 32: The US Bio Diesel Lifecycle
Figure 33: The US Biofuel Market Segmentation by Fuel Ethanol and Bio Diesel on the Basis of Production in Thousands Barrels per Day, 2006-2011
Figure 34: The US Biofuel Market Segmentation by Fuel Ethanol and Bio Diesel on the Basis of Consumption in Thousands Barrels per Day, 2006-2011
Figure 35: The US Biofuel Market Projections by Revenue in USD Million, 2012-2016
Figure 36: The US Bio Enzymes Market Size in USD Million, 2006-2011
Figure 37: Market share of Major Companies in the US Enzymes Market, 2011
Figure 38: Novozymes Total Sales in USD Million, 2007-2011
Figure 39: Novozymes R&D Costs in USD Million, 2007-2011
Figure 40: The US Bio-Enzymes Market Size in USD Million, 2012-2016
Figure 41: The US Industrial Biotechnology Market Size in USD Million, 2012-2016
Figure 42: The US Biotechnology Market Size in USD Million, 2012-2016
LIST OF TABLES
Table 1: The US Sales of Top Selling Global Biologic Drugs, USD billion, 2010
Table 2 : Bio-Pharmaceutical Products Approved By FDA in 2010 (until mid September)
Table 3: Leading Biopharmaceutical Companies in the US by Sales in USD Billion, 2011
Table 4: Pfizer’s Product Patent Expiration Year
Table 5: Top Selling Pfizer’s Biopharmaceutical Products in the US in USD Million, and their Revenue Contribution in Percentage, 2011
Table 6: Merck’s Top Pharmaceutical Drug Sales in the US in USD Million, 2010-2011
Table 7: Novartis’ Revenue Segmentation by Pharmaceutical and Sandoz Division in the US in USD Billion, 2005 - 2011
Table 8: Novartis’ Top Pharmaceutical Drug Sales in the US in USD Million, 2011
Table 9: Astra Zeneca’s Pharmaceutical Drug Sales in the US by Product and Therapeutic Category in USD Million, 2011
Table 10: GlaxoSmithKline’s Top Selling Pharmaceutical Drugs in the US in USD Million, 2011
Table 11: Demographic Distribution of Population in US on the basis of Age, in Million, 2009-2012
Table 12: Company Profile of Major Companies in the US Agricultural Biotechnology, 2011
Table 13: The US Biofuel Market Segmentation by Fuel Ethanol and Bio Diesel on the Basis of Production and Consumption in Thousands Barrels per Day, 2012-2016
Table 14: Cause and Effect Relationship Analysis between Industry Factors and Expected Industry Prospects of the US Biotechnology Industry
Table 15: Correlation Matrix
Table 16: Regression Coefficients Output
Table 1: The US Sales of Top Selling Global Biologic Drugs, USD billion, 2010
Table 2 : Bio-Pharmaceutical Products Approved By FDA in 2010 (until mid September)
Table 3: Leading Biopharmaceutical Companies in the US by Sales in USD Billion, 2011
Table 4: Pfizer’s Product Patent Expiration Year
Table 5: Top Selling Pfizer’s Biopharmaceutical Products in the US in USD Million, and their Revenue Contribution in Percentage, 2011
Table 6: Merck’s Top Pharmaceutical Drug Sales in the US in USD Million, 2010-2011
Table 7: Novartis’ Revenue Segmentation by Pharmaceutical and Sandoz Division in the US in USD Billion, 2005 - 2011
Table 8: Novartis’ Top Pharmaceutical Drug Sales in the US in USD Million, 2011
Table 9: Astra Zeneca’s Pharmaceutical Drug Sales in the US by Product and Therapeutic Category in USD Million, 2011
Table 10: GlaxoSmithKline’s Top Selling Pharmaceutical Drugs in the US in USD Million, 2011
Table 11: Demographic Distribution of Population in US on the basis of Age, in Million, 2009-2012
Table 12: Company Profile of Major Companies in the US Agricultural Biotechnology, 2011
Table 13: The US Biofuel Market Segmentation by Fuel Ethanol and Bio Diesel on the Basis of Production and Consumption in Thousands Barrels per Day, 2012-2016
Table 14: Cause and Effect Relationship Analysis between Industry Factors and Expected Industry Prospects of the US Biotechnology Industry
Table 15: Correlation Matrix
Table 16: Regression Coefficients Output
